This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NanoVibronix 대차 대조표 상태

재무 상태 기준 확인 6/6

NanoVibronix has a total shareholder equity of $3.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.9M and $2.6M respectively.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$2.71m
주식	US$3.23m
총 부채	US$2.65m
총 자산	US$5.88m

최근 재무 상태 업데이트

Recent updates

재무 상태 분석

단기부채: 56R0's short term assets ($5.6M) exceed its short term liabilities ($2.3M).

장기 부채: 56R0's short term assets ($5.6M) exceed its long term liabilities ($330.0K).

부채 대 자본 내역 및 분석

부채 수준: 56R0 is debt free.

부채 감소: 56R0 had no debt 5 years ago.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: 56R0 has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.

예측 현금 활주로: 56R0 is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.

This company listing is no longer active

NanoVibronix 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

NanoVibronix Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

NanoVibronix, Inc. announced delayed annual 10-K filing

NanoVibronix Regains Nasdaq Compliance

NanoVibronix Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement

NanoVibronix, Inc. announced delayed annual 10-K filing

Recent updates

NanoVibronix, Inc. Announces Commencement of UroShield Clinical Study at the University of Michigan

NanoVibronix Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

NanoVibronix, Inc. announced delayed annual 10-K filing

NanoVibronix Regains Nasdaq Compliance

NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff

NanoVibronix, Inc. announced that it expects to receive $5 million in funding

NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff

NanoVibronix Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Insufficient new directors

NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus

Third quarter 2022 earnings released: US$0.034 loss per share (vs US$0.26 loss in 3Q 2021)

Insufficient new directors

Nanovibronix, Inc. Announces Interim Results of Clinical Study for UroShield

NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement

Insufficient new directors

Insufficient new directors

NanoVibronix, Inc., Annual General Meeting, Sep 14, 2022

Insufficient new directors

Insufficient new directors

Nanovibronix, Inc. Announces FDA 510(K) Submission for Painshield MD Plus

NanoVibronix, Inc. Adds Additional Product to Federal Supply Schedule

NanoVibronix, Inc. announced delayed annual 10-K filing

NanoVibronix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

NanoVibronix Files Three U.S. Patent Applications Further Leveraging Its Innovative Surface Acoustic Wave Technology

NanoVibronix, Inc. Announces Positive Interim Results from Independent, Real World Patient Study of its UroShield

Third quarter 2021 earnings released: US$0.25 loss per share (vs US$0.099 loss in 3Q 2020)

NanoVibronix, Inc. Launches New, Transdermal Gel Containing Nano-Cannabidiol for the Treatment of Joint Pain and Reducing Inflammation

Insufficient new directors

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기